1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine, 390(11), 1033–1045. https://doi.org/10.1056/NEJMoa2416394
3. Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Bethel, M. A., & Cox, D. A. (2021).Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care, 44(3), 765–773. https://doi.org/10.2337/dc20-1473
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. Zipursky, J. S., Bogler, T., & Maxwell, C. (2024, December 15). Glucagon‑like peptide‑1 receptor agonists during pregnancy and lactation. Canadian Medical Association Journal, 196(43), E1413–E1415. https://doi.org/10.1503/cmaj.240768
6. https://therxadvocates.com/blog/victoza-weight-loss/
7. https://community.the-hospitalist.org/content/glp-1-ras-when-not-prescribe
8. 藥品仿單查詢平台